Attendee search 

Ethypharm is a rapidly growing specialty pharma company with nascent commercial operations, an expanding portfolio of marketed products, a unique drug development expertise and a broad and advanced pipeline.

Ethypharm now incorporating Martindale Pharma of the UK focuses on pain management and treatment for addiction, particularly opioids and alcohol use disorder; with the current short-term goal to commercialize its own or in-licensed drugs in a number of European countries.

In other therapeutic areas, mainly oncology, Ethypharm has a strong capability in developing and manufacturing specific and "complex" drug formulations in order to market them through global or local partners.

Ethypharm’s headquarters are located in Paris, France and has a very strong affiliate in the UK, it owns two manufacturing plants in France, one in China, and an affiliate in the USA.
 
Ethypharm is actively seeking:

• Licensing-in/acquisition opportunities in pain and addiction (to opioids, alcohol, tobacco) , critical care, complex generics, brands, late stage NCEs, Steriles/Injectables, Hospital products);

Present Value specialise in acquisition, divestment, licensing, partnering and strategy in life science. Our experience is purely pharmaceutical and anyone who works on your prospective project will have worked in the industry for some time.  Of course, we also benefit hugely from an excellent network that has been built organically through our project work (a recent project may saw us liaising with more than one hundred companies across Europe as an example).

Recently celebrating over 10 years of success for our clients, Present Value was founded back in 2007. You can get a flavour of the types of projects and transactions we work on by looking at some of the cases histories on our website.  Alternatively, please see below for a synopsis...

1. Acquire - We will find you new targets:

·         It is difficult to find businesses or assets to acquire, especially the right shape and size for your business. We have a structured way of hunting for deals and maintain a database of potential sellers. We can be your extra set of eyes and ears out there.

2. Divest - You deserve the right value for your asset or company:

·         We would not call a company Present Value if we did not understand the equation. It is not just about an equation, it is about a thorough understanding of what drives the value in your business. We have developed an efficient process to gain you best value for your asset. You get on with running your business while we organise all the relevant documentation and deal with potential buyers.

3. Licensing - Take the essential route to pharmaceutical licensing:

·         We spend a lot of time at the pharmaceutical industry’s partnering meetings and have a good idea of what each company is looking for or what they might be offering. We tend to stick to branded innovative licensing.

4. Consulting - Expert analysis on every aspect in business of Life Science:

·         If you are struggling with something or looking to get some fresh ideas, we work on all sorts of business development projects and strategies. They are always about unlocking extra value and getting the best out of your assets.

All our projects are bespoke to you and should your project require more specialist corporate finance, regulatory or legal input we can cover that too and tend to put together a bespoke team of competent individuals or complimentary firms.

Our past and current clients range from individual entrepreneurs, family firms, country subsidiaries and global entities.  We are proud of our track record of repeat and continuing business from a number of our clients, many of whom have taken us with them when they move to a new company.

If you would like to have a chat about how we can help, please call on +44 (0) 1892 825663 or if you at any PLG, EMIG, Bio Europe event, we’re likely to be there too.

We’re generally useful to know and we look forward to hearing from you.

Both Andrew Dean and Adam Minshall are available for meetings in Montreux.  Alternatively, why not just find either of us for an informal chat.

Alliance Pharma is an internation specialty pharma busienss with a buy and build business model and asset light operations. We have a balanced portoflio of growth focussed international star brands and a cash-generative Bedrock requiring minimal promotional support. We have 20 years of operation, 35 deals experience and have been on the London stock exchange junior market (AIM) since 2003 (LSE: APH). 2017 results: £100m+ sales, 27% EBITDA, £20m+ FCF, dividend paying Our star brands are: Kelo-cote – fastest drying, silicone gel anti-scar treatment  MacuShield – exact match to the protective pigments found on the macula Vamousse – most technologically advanced treatment for head lice Nizoral – medicated anti-dandruff shampoo acquired from J&J in June 2018      

Chugai Pharma Europe Ltd. is seeking for in-licensing and partnering opportunities for its European key territories in UK, Germany and France. We strive to build our business model on existing partnerships in oncology/hematology and rheumatology as well as to grow as a organization with strong commercialization expertise, broad market access and pricing knowledge and valuable experience in medical advocacy and KOL Management.

We look forward to meeting you in Montreux,

Ryo ishimura and Florian Streckert